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Abstract
Background: Enhancer of zeste homolog 2 (EZH2) is considered an important driver of tumor development and
progression by its histone modifying capabilities. Inhibition of EZH2 activity is thought to be a potent treatment
option for eligible cancer patients with an aberrant EZH2 expression profile, thus the indirect EZH2 inhibitor 3-
Deazaneplanocin A (DZNep) is currently under evaluation for its clinical utility. Although DZNep blocks proliferation
and induces apoptosis in different tumor types including lymphomas, acquired resistance to DZNep may limit its
clinical application.
Methods: To investigate possible mechanisms of acquired DZNep resistance in B-cell lymphomas, we generated a
DZNep-resistant clone from a previously DZNep-sensitive B-cell lymphoma cell line by long-term treatment with
increasing concentrations of DZNep (ranging from 200 to 2000 nM) and compared the molecular profiles of resistant
and wild-type clones. This comparison was done using molecular techniques such as flow cytometry, copy number
variation assay (OncoScan and TaqMan assays), fluorescence in situ hybridization, Western blot, immunohistochemistry
and metabolomics analysis.
Results: Whole exome sequencing did not indicate the acquisition of biologically meaningful single nucleotide
variants. Analysis of copy number alterations, however, demonstrated among other acquired imbalances an
amplification (about 30 times) of the S-adenosyl-L-homocysteine hydrolase (AHCY) gene in the resistant clone. AHCY is
a direct target of DZNep and is critically involved in the biological methylation process, where it catalyzes the reversible
hydrolysis of S-adenosyl-L-homocysteine to L-homocysteine and adenosine. The amplification of the AHCY gene is
paralleled by strong overexpression of AHCY at both the transcriptional and protein level, and persists upon culturing
the resistant clone in a DZNep-free medium.
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Conclusions: This study reveals one possible molecular mechanism how B-cell lymphomas can acquire resistance to
DZNep, and proposes AHCY as a potential biomarker for investigation during the administration of EZH2-targeted
therapy with DZNep.
Keywords: 3- Deazaneplanocin a (DZNep), B-cell lymphoma, Enhancer of zeste homolog 2 (EZH2), S-adenosyl-L-
homocysteine hydrolase (AHCY)
Background
The development of drug resistance to cancer chemo-
therapeutics remains a major concern in most treatment
regimens. Several epigenetic-based therapies are under
investigation or being employed for treatment of patients
with lymphomas of B-cell origin. This is due to the im-
portant role that epigenetic alterations play in promoting
tumor development and progression via downregulation
of tumor suppressor genes [1]. These epigenetic modifi-
cations may involve covalent post-translational modifica-
tions at the N-termini of histones or changes in the
methylation pattern of cytosine bases within the DNA,
especially at CpG sites [2]. Histones are important struc-
tural components of the cell that package and organize
DNA into nucleosomal units and various post-
translational modifications of histones are known to
contribute to transcriptional gene activity in conjunction
with other mechanisms [3–8].
Enhancer of zeste homolog 2 (EZH2) is a histone methyl-
transferase that is involved in cellular differentiation and de-
velopment in both health and disease. EZH2 promotes
transcriptional repression by catalyzing the trimethylation of
lysine 27 on histone 3 (H3K27me3) - a repressive histone
mark. In lymphoma and other malignancies, EZH2 gain-of-
function mutations and overexpression are considered im-
portant drivers of oncogenesis because of their role in
silencing tumor suppressor genes regulating apoptosis, cell
cycle regulation, proliferation, migration and differentiation
[9–14]. Due to its oncogenic role, the targeting of EZH2
might be a promising approach for lymphoma therapy. 3-
Deazaneplanocin A (DZNep) is an indirect inhibitor of
EZH2 currently in the pre-clinical phase of drug develop-
ment and has been shown to promote apoptosis in various
primary tumor cells and cancer cell lines [15–20]. The apop-
totic effects mediated by DZNep application are more pro-
nounced in cancer cells, with minimal effects on normal
cells, and are fostered by the inhibition of the repressive
H3K27me3 mark [15, 18, 21].
DZNep directly inhibits the enzyme S-adenosyl-L-
homocysteine hydrolase (AHCY) that catalyzes the re-
versible hydrolysis of S-adenosyl-L-homocysteine (SAH)
to L-homocysteine and adenosine. The direct inhibition
of AHCY by DZNep leads to the build-up of the sub-
strate SAH, which in turn causes a negative feedback in-
hibition of methyltransferases such as EZH2 [22]. Proper
functioning of AHCY is essential for the efficient main-
tenance of histone methylation levels in the cell [23]. Al-
terations in AHCY function have been linked to cancer
with varying outcomes depending on the cancer entity
involved. For example, with lowered AHCY activity, the
invasiveness of breast cancer and glioblastoma cell lines
decreases [24, 25]. Furthermore, in hepatocellular carcin-
oma cells, reduced AHCY activity is associated with cell
cycle inhibition and a lowered proliferation rate [23]. In
esophageal squamous cell carcinoma, however, elevated
AHCY levels had no effect on cell proliferation but pro-
moted apoptosis and inhibited cell migration and adhe-
sion [26]. Besides, aberrant AHCY expression has been
observed with the transformation of follicular lymphoma
to diffuse large B-cell lymphoma [27].
In this study, we investigated the underlying molecular
mechanism of resistance of a B-cell lymphoma model to
DZNep using a DZNep-resistant clone generated from a
DZNep-sensitive cell line. We identified AHCY as a po-
tential biomarker that could be of predictive relevance
for therapeutic inhibition of EZH2 using DZNep.
Methods
Drug, cell lines and culture conditions
DZNep (Selleckchem, Germany) was dissolved in sterile
water following the manufacturer’s recommendation as
previously described [20].
The sporadic Burkitt lymphoma cell line BLUE-1
(ACC-594, from German Collection of Microorganisms
and Cell Cultures (DSMZ) Germany) was cultured in
RPMI 1640 (ThermoFisher Scientific, Germany) medium
enriched with 20% fetal calf serum (PAN-Biotech,
Germany). Cell lines were tested and confirmed myco-
plasma negative with the MycoAlert Mycoplasma Detec-
tion kit (Lonza, Germany). All cell lines were incubated
at 37 °C at 5% CO2.
Generation of a DZNep resistant clone was achieved
by splitting the BLUE-1 culture into a control group and
a treatment group (Fig. 1a). The treated group received
increasing concentrations of DZNep starting from 200
nM up to 2000 nM over a period of 7 months. The cells
were split 3 times a week and fresh medium without or
with DZNep was added to the control and treated cells,
respectively. Vital cells were counted each time by flow
cytometry before the cells were split. Cryostocks were
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made every third to fourth week from both cell cultures.
At 7 months, DZNep pressure on cultures of the treated
group was removed by growing both untreated (BLUE-1
K10) and treated (BLUE-1R10) cells in medium without
DZNep. About 4 months later, both cell cultures were
harvested (BLUE-1 K12 and BLUE-1R12) and frozen.
Prior to further use, frozen cells were thawed and main-
tained in a DZNep-free medium for at least 1 week.
Flow cytometry
The BD Accuri C6 flow cytometer (Becton Dickinson
Biosciences, USA) was used for the measurement of
apoptotic cells and determination of the doubling time
of cells. Measurement of apoptosis was performed after
staining 3 × 105 cells from the cell cultures with a mix-
ture of Annexin V (Biolegend, USA) and propidium iod-
ide (Biolegend, USA). Doubling time was determined by
Fig. 1 Generation and characterization of a DZNep-resistant clone. a Scheme of the generation of the DZNep-resistant clone and its control. b
Comparison of the apoptotic response of BLUE-1 K10 (control) and BLUE-1R10 to DZNep. Above: The cell lines BLUE-1R10 and BLUE-1 K10 were
either treated with 5 μM DZNep or untreated for 72 h. Cells were harvested and the percentage of apoptotic cells was determined by flow
cytometry. Data is shown as mean plus standard deviation (SD) of three biological replicates. Below: Western blot analysis was performed using
total protein lysates from both cell lines either untreated or treated with 2 μM and 5 μM DZNep, respectively. GAPDH was used as a loading
control for the Western blot. The full-length blot is presented in Additional file 6: Fig. S5. The FUSION-CAP Software was used for Western blot
image analysis. c Comparison of the doubling time of BLUE-1, BLUE-1 K10 and BLUE-1R10. The three cell lines were cultivated at a seeding
density of 2 × 105 cells in 6-well culture plates. The number of vital cells were measured at 24 h, 48 h and 72 h by flow cytometry. Doubling time
is shown as mean plus SD of triplicate measurements. ns: not significant
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seeding the cells in 6-well plates at a cell density of 2 ×
10^5 cells/ml. The number of vital cells were counted
after 24 h, 48 h and 72 h by flow cytometry. The doub-
ling time during the exponential growth phase was sub-
sequently calculated using the formula DT = Tln2/ln(Xe/
Xb) (https://www.atcc.org/~/media/PDFs/Culture%2
0Guides/AnimCellCulture_Guide.ashx), where DT rep-
resents the doubling time (in hours), T symbolizes the
incubation time (in hours), Xe indicates the cell number
at the end of the incubation time, and Xb is the cell
number at the beginning of the incubation time.
Western blotting, RNA isolation and real-time reverse
transcriptase polymerase chain reaction (RT-PCR)
Cell lysis and Western blot were carried out as described
previously [20]. Twelve percent Expedeon RunBlue SDS
protein gels (Biozol Diagnostica Vertrieb GmbH,
Germany) were utilized for the run. The primary and
secondary antibodies used for Western blot are shown
in Table 1.
RNA was isolated using the RNeasy Midi Kit (Qiagen,
Germany) adhering to the manufacturer’s recommenda-
tions and reverse transcribed to cDNA using TaqMan
Reverse Transcription reagents (ThermoFisher Scientific,
Germany) on a T3 thermocycler (Biometra GmbH,
Germany). Real-time RT-PCR was carried out using
TaqMan Gene Expression Assays and TaqMan Gene Ex-
pression Master Mix (ThermoFisher Scientific,
Germany) following the manufacturer’s protocol on the
StepOnePlus Real-Time PCR System (ThermoFisher Sci-
entific, Germany). Beta-2 microglobulin (B2M) and suc-
cinate dehydrogenase (SDHA) genes were used as
endogenous controls and the ΔΔCt method [28] was
followed for relative mRNA quantification. Details of the
respective TaqMan assays used are listed in Table 2.
DNA isolation, whole exome sequencing (WES), copy
number variation (CNV) assay and OncoScan CNV assay
Genomic DNA was isolated from the cell lines using
QIAamp DNA Mini Kit (Qiagen, Germany), following
the manufacturer’s instructions. WES was performed on
genomic DNA at the Berlin Institute of Health core fa-
cility Genomics, Berlin, Germany. Sequencing libraries
were prepared with the SureSelectXT Human All Exon
v4 library kit (Agilent, Germany) following the manufac-
turer’s instructions. Cluster Generation was done with
the aid of TruSeq PE Cluster Kit v4 (Illumina, USA) and
the resulting templates sequenced on an Illumina
HiSeq2000 sequencer (at least 150 million reads with a
sequencing depth of greater than 160x) using the Illu-
mina HiSeq SBS 250 cycle kit v4.
Data analysis was performed using BWA-MEM [29] to
map each whole-exome data set against the reference
genome GRCh37. Samblaster [30] was used to mark du-
plicates. To detect copy number changes, DNA profiles
from the respective cell lines were compared (BLUE-
1R10 against BLUE-1 K10) with CNVkit [31]. The copy
number changes were prioritized according to their log2
fold-change and custom plots of amplified regions cre-
ated using CNVkit plotting functions.
CNV analysis was performed on genomic DNA from
the respective BLUE-1 cell lines, controls and patient
samples by applying the TaqMan copy number assay
(assay ID: Hs02422126_cn) to the AHCY gene on
chromosome 20. The assay covers intron 7 and exon 8
on the reference genome GRCh37 and was performed
according to the manufacturer’s recommendations. Data
Table 1 List of antibodies
Target Protein Primary antibody
Application Company Clone name / catalogue number
Western blot Immunohistochemistry
GAPDH ✓ Cell Signaling Technology 14C10
Histone 3 ✓ Cell Signaling Technology 96C10
Cleaved PARP ✓ Cell Signaling Technology Asp214
AHCY ✓ ✓ OriGene TA332593
Secondary antibody
Anti-rabbit HRP-conjugated ✓ GE Healthcare NA934V
Anti-mouse HRP-conjugated ✓ Agilent P0447
Table 2 TaqMan assays used for gene expression and copy
number variation (CNV) analysis
TaqMan Assays
Targets Assay ID Type Company
cDNA
target
AHCY Hs00898137_g1 Gene expression
assay
ThermoFisher
Scientific
B2M Hs00984230_m1 Gene expression
assay
ThermoFisher
Scientific
SDHA Hs00417200_m1 Gene expression
assay
ThermoFisher
Scientific
gDNA
target
AHCY Hs02422126_cn CNV assay ThermoFisher
Scientific
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analysis was done using the CopyCaller software version
2.1 (ThermoFisher Scientific, Germany).
OncoScan CNV assay Kit was also used to perform
copy number analysis according to standard protocols
(Affymetrix) [32]. The Chromosome Analysis Suite 4.0
(ChAS) (ThermoFisher, Germany) software was used to
visualize, analyze and summarize the chromosomal aber-
rations, including gains, losses, and loss of heterozygosity
(LOH). The non-FFPE analysis work-flow was applied.
Criteria for copy number alterations include chromo-
somal changes encircling at least 20 informative probes,
with a minimum size event of at least 100 kb, with me-
dian log2Ratio +/− 0.3, and showing a CNN-LOH more
than 5Mb. Individual copy number analysis for each
BLUE-1 cell line, as well as, comparative analysis be-
tween the three cell lines (BLUE-1, BLUE-1 K10, and
BLUE-1R10) was done. In addition, we manually
inspected all the aberrations filtered out due to the cri-
teria described above and included only those aberra-
tions showing differences in the B-allele frequency
(BAF).
Clonality studies
B-cell clonality studies were performed to determine the
immunoglobulin heavy chain (IGH) rearrangements for
BLUE-1, BLUE-1 K10 and BLUE-1R10 using a multiplex
PCR method developed within the EuroClonality/
BIOMED-2 collaborative study, BMH4-CT98–3936 [33]
for all three IGH frame work regions. After PCR on the
ProFlex PCR Thermocycler (ThermoFisher Scientific,
Germany), gel electrophoresis was performed to check
the amplification of PCR products. For single base pair
resolution, GeneScan analysis (capillary electrophoresis)
of the IGH PCR products was performed with the 3500
series Genetic Analyser (ThermoFisher Scientific,
Germany). The sizes of the various PCR products were
determined using the GeneMapper 4.0 software (Ther-
moFisher Scientific, Germany).
Immunohistochemistry and fluorescence in situ
hybridization (FISH) analysis
Immunohistochemistry (IHC) was performed using sec-
tions of formalin-fixed paraffin-embedded (FFPE) cell
line blocks as described [34]. The primary antibody used
in this case was anti-AHCY antibody (Table 1). FISH
was performed on sections of formalin-fixed paraffin-
embedded (FFPE) cell line blocks as described [35, 36].
This was carried out using orange-labeled AHCY gene-
specific probes (product name: AHCY-20-OR) and
green-labeled chromosome 20-control (centromeric)
probes (product name: CHR20–10-GR) (both purchased
from Empire Genomics, USA). DakoCytomation
Hybridizer (Dako/Agilent, Germany) was used for FISH
probe hybridization, while nuclear counterstaining was
done with the aid of Dako fluorescence mounting
medium containing DAPI (Dako/Agilent, Germany).
Visualization and analysis (of at least 50 intact nuclei)
were performed with the Zeiss Axio Imager Z1 (Zeiss,
Germany) and the Isis imaging software version 5.3.1
(Metasystems, Germany).
Cytogenetics, metabolomics and global DNA methylation
analysis
Profiling of short tandem repeats (STR) for authentica-
tion of the cell lines BLUE-1, BLUE-1 K10 and BLUE-
1R10 using the StemElite kit (Promega) was performed
as previously described [32]. Conventional cytogenetic
analysis was performed as reported [37] and the karyo-
types were described according to ISCN guidelines
(2013).
The intermediates of methionine and polyamine me-
tabolism in BLUE-1, BLUE-1 K12 and BLUE-1R12 cell
extracts were measured by liquid chromatography-
tandem mass spectrometry following an established
protocol [38]. Genome-wide DNA methylation analysis
was done on BLUE-1, BLUE-1 K10 and BLUE-1R10
using the Infinium MethylationEPIC BeadChip (Illu-
mina, USA) as described [39]. Copy number plots were
generated from the raw output data (.idat files) using
the ‘conumee’ R package in Bioconductor [39, 40].
Statistical analysis
Statistical analysis was done using the GraphPad Prism 5
software (GraphPad Software, California, USA). Statis-
tical significance was evaluated using the Mann-Whitney
U test (two-tailed) for pairwise comparisons, and one-
way ANOVA with the Tukey post-hoc test for group
comparisons. p values less than 0.05 were considered
significant.
Results
Generation and characterization of a DZNep-resistant cell
line clone
We generated a DZNep-resistant clone by subjecting the
DZNep-sensitive Burkitt lymphoma cell line BLUE-1
[20] to progressively increasing concentrations of
DZNep for up to 7 months (Fig. 1a and Methods sec-
tion). Analyses were performed with the resistant BLUE-
1 subclones (BLUE-1R10 or BLUE-1R12) and their re-
spective controls. To analyze the response of the gener-
ated DZNep-resistant clone to DZNep, we treated the
clone and its corresponding control with 5 μM DZNep
for 72 h and then measured the percentage of apoptotic
cells. The control cell line, BLUE-1 K10, exhibited strong
apoptosis with about 50% apoptotic cells in comparison
to the resistant BLUE-1R10 clone, which displayed only
about 10% apoptotic cells following treatment with
DZNep (Fig. 1b). Furthermore, Western blot analysis
Akpa et al. BMC Cancer          (2020) 20:427 Page 5 of 12
performed on total protein lysate obtained after treat-
ment of both cell lines with 2 μM and 5 μM DZNep re-
vealed an increase in the expression of cleaved PARP,
indicating apoptosis in the DZNep-treated cells of
BLUE-1 K10 in relation to BLUE-1R10 (Fig. 1b). The
doubling time of the DZNep-resistant clone BLUE-1R10
was also compared with that of the corresponding con-
trol BLUE-1 K10 and the parent cell line BLUE-1. This
revealed that both BLUE-1R10 and BLUE-1 K10 had
shorter doubling times than BLUE-1 (Fig. 1c).
To determine the identity of the generated clone, we
explored the STR profile and determined the clonality of
BLUE-1R10. The results were then compared with those
of its corresponding control BLUE-1 K10 and the parent
cell line BLUE-1. The STR profile analysis for the three
cell lines when compared with the DSMZ STR profiling
database revealed an STR profile of a BLUE-1 cell line,
confirming their authenticity. Furthermore, the IGH
chain gene rearrangement patterns for the three cell
lines were identical (Additional file 1: Figure S1). We
also performed genomic characterization of the cell lines
using conventional cytogenetics and copy number ana-
lysis by OncoScan CNV assay. Only minor differences in
the karyotype were observed upon analysis of the three
cell lines (Additional file 2: Figure S2). Upon further
examination the copy number data, we detected gen-
omic aberrations exclusive to each of the three BLUE-1
cell lines (Additional file 5: Table S1). We detected three
abnormalities only present in BLUE-1R10 as compared
to the parental BLUE-1 and BLUE-1 K10 cell lines.
These include one loss in 4q12q12, one high copy gain
in 6q14.3q14.3, and one LOH in 20p12.2p13. Moreover,
we observed aberrations solely in the parental BLUE-1
cell line, including gains in 6p22.1p25.3, 19p13.11p13.3,
and 19p13.11q13.43, which may have been lost due to
prolonged culture conditions. We also distinguished
common copy number aberrations in BLUE-1 and
BLUE-1R10 cell lines, but not shown in the BLUE-1 K10
(Additional file 5: Table S1).
Identification of biomarkers for resistance to DZNep
To probe the underlying mechanism of resistance of
BLUE-1R10 to DZNep, we performed WES of genomic
DNA obtained from BLUE-1R10 and its corresponding
control BLUE-1 K10. Additional copy number variant
analysis was performed on the WES data using the soft-
ware tool CNVkit. This analysis identified a small focal,
approximately 30-fold copy number gain in the region
spanning the AHCY gene and the proximal part of the
ITCH gene on chromosome 20 (Fig. 2a). Upon manual
inspection of this specific genomic region in the OncoS-
can data, we confirmed the presence of this high copy
number gain including the AHCY gene (Additional file
3: Figure S3). It was not called in the initial analysis due
to applied detection criteria for the analysis which fil-
tered the amplicon out due to its small genomic size and
low marker content (see material and method sections
for more details).
We validated this AHCY gain on the DNA level using
two methods. First, we used the TaqMan Copy Number
Assay to analyze DNA obtained from cryostocks col-
lected at the various time-points during the generation
of the resistant clone, including BLUE-1 as the reference
cell line. We noted a clear copy number gain in AHCY
beginning with BLUE-1R6 (preserved after almost 5
months of treatment with DZNep) and increasing there-
after (Fig. 2b). The AHCY copy number gain was further
confirmed by a CNV analysis using global DNA-
methylation data from BLUE-1R10, and comparing it
with data from BLUE-1 K10 and BLUE-1. Here, the gain
in AHCY copy number on chromosome 20 was also ob-
vious in the resistant clone in comparison to the respect-
ive control and the parent cell line (Fig. 2c).
AHCY copy number gain at the chromosomal and
transcriptional level
On the chromosomal level, we confirmed AHCY amplifi-
cation in BLUE-1R10 and BLUE-1R12, by performing a
FISH study using target-specific probes for AHCY on
chromosome 20q11.22. Our FISH data (Fig. 3a) revealed
cluster-type amplification and large AHCY-gene clusters
in form of dense clouds of labeled regions suggestive for
hsr-regions in cells of BLUE-1R10, when compared with
its control BLUE-1 K10 and BLUE-1.
To ascertain the expression of AHCY, we performed a
real-time PCR using the TaqMan gene expression assay
on cDNA from the resistant clone, the respective con-
trols and the parent cell line BLUE-1. The results display
overexpression of AHCY in the resistant clone BLUE-
1R10 and a further increase in BLUE-1R12 (Fig. 3b).
AHCY gain at the protein level and metabolomics studies
AHCY expression at the protein level was determined
using two different methods, IHC and Western blot. The
IHC results show increased AHCY expression in the re-
sistant clone in comparison to its control and the parent
cell line (Fig. 4a). The Western blot result (Fig. 4b) con-
firmed that AHCY is overexpressed in BLUE-1R10, with a
higher expression in BLUE-1R12. The respective controls
and parent BLUE-1 cell line had a similar level of AHCY
expressed.
To understand the dynamics of the concentrations of
methionine intermediates in the resistant clone, its con-
trol and the parent cell line, we employed a high per-
formance liquid chromatography-tandem mass
spectrometry method. We notice a similar distribution
pattern for S-adenosyl-L-homocysteine (SAH), adenine
and adenosine in BLUE-1 and the control cell line
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BLUE-1 K12. The resistant clone (BLUE-1R12), however,
displayed a significant increase (p < 0.05) in the level of
both adenine and adenosine in comparison to its control
BLUE-1 K12 (Fig. 4c).
AHCY copy number gain in primary lymphoma samples
We examined the frequency of AHCY copy number gains
in a small series of B-cell lymphomas by examining 12 pri-
mary lymphoma samples consisting of Burkitt lymphoma,
diffuse large B-cell lymphoma, follicular lymphoma, pri-
mary mediastinal B-cell lymphoma and anaplastic large
cell lymphoma. We performed the TaqMan CNV assay
using genomic DNA isolated from these samples. Subse-
quent analysis of the AHCY copy number with the Copy-
Caller software revealed a predicted AHCY copy number
of 2 for all but one sample, which had a predicted copy
number of 1 (Additional file 4: Figure S4). In addition, we
checked the frequency of AHCY copy number alterations
in B-cell lymphoma by analyzing published genomic data
from 1295 B-cell lymphoma samples curated from 5
different studies on the cBio Cancer Genomics Portal
[41, 42] but no AHCY genomic alterations were
detected.
Discussion
Acquired resistance to small molecule inhibitors used in
cancer treatment remains a huge problem in cancer
therapy. Although many cancer types respond to initial
therapy, there is the uncertainty of resistance arising
against the utilized drug [43]. Various molecular
Fig. 2 AHCY copy number gain in the DZNep-resistant clone. a Log2 copy ratio plot of copy number variation regions in BLUE-1R10 in relation to
BLUE-1 K10. The gray dots represent copy ratio values across different bins, the orange line shows segments and the yellow vertical lines indicate
the respective genes. b Evolution of AHCY copy number in the resistant clone. Genomic DNA from the cell lines was subjected to the TaqMan
copy number assay (ID: Hs02422126_cn). The real-time PCR read-out and copy number was analyzed with the CopyCaller software. A human
tonsil DNA sample was used as a calibrator for the TaqMan copy number assay. c CNV plots calculated from global DNA methylation array data.
Chromosome 20 locus on BLUE-1, BLUE-K10 and BLUE-1R10 was analyzed for variations in AHCY copy number. The y-axis represent the log2 copy
number ratio (CNR). Amplifications represent positive deviations from the baseline while losses indicate negative deviations from the baseline
(0.0). Encircled in red, shows AHCY copy number gain in BLUE-1R10
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mechanisms are involved in the resistance of tumor cells
to therapy [44–46]. DZNep - an indirect EZH2 inhibitor
- is known to be efficacious against many different types
of cancer and, hence, may make its way into clinical tri-
als. Already, genetic determinants of sensitivity to
DZNep-mediated apoptosis have been described for gas-
tric cancer and multiple myeloma tumor cells respect-
ively [47, 48]. In this study, we aimed to investigate the
molecular mechanism underlying acquired resistance to
DZNep in B-cell lymphoma, and to identify biomarkers
predictive of the therapeutic success of EZH2 inhibition
with DZNep. To achieve this, we generated and investi-
gated a DZNep-resistant clone. The continued resistance
of the clone (BLUE-1R10) to DZNep following treatment
with DZNep as well as upon cultivation in a DZNep-free
medium implies that a permanent change has occurred
on the genomic level in this clone. We analyzed the
proliferation rate of BLUE-1R10, comparing its doubling
time with that of BLUE-1 K10 and BLUE-1. The shorter
doubling time observed in the resistant clone and its
control in relation to the parent cell line is in contrast to
a previous report of an increased doubling time in two
colon cancer cell lines that acquired drug resistance
upon prolonged cultivation with irinotecan [49]. Since
the reduction in doubling time was also observed in the
control cell line BLUE-1 K10, the increased growth rate
of both BLUE-1R10 and BLUE-1 K10 cannot be attrib-
uted to the effect of DZNep on the cells. Perhaps, some
changes in genes responsible for cell cycle regulation
and proliferation could have occurred during the long-
term cultivation of the clone and its control. This is not
surprising because, we already know the extent of gen-
etic and transcriptional heterogeneity that occur in cell
lines during evolution [50]. Besides, in other cell types
Fig. 3 AHCY copy number gain in the DZNep-resistant clone: chromosomal and transcriptional validation. a FISH analysis using AHCY target-
specific probes in the resistant clone and its control. Yellow arrows show in pink color a cluster-type amplification of AHCY. Green dots represent
the centromere of chromosome 20. b Transcriptional expression of AHCY. cDNA was synthesized from the RNA of all cell lines. Relative gene
expression (shown on the y-axis) was quantified using the AHCY gene expression assay, with B2M and SDHA used as an endogenous control. RQ
is shown as mean plus SD of triplicate measurements
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such as human embryonic stem cells, the effect of pro-
longed cultivation on the proliferative capacity is evident
as an increase in the proliferative capacity of these cells
[51].
It was crucial to confirm the identity of the DZNep-
resistant clone to ensure that it certainly originated from
the parent cell line BLUE-1. To achieve this, the STR
profile and clonality of BLUE-1R10 was explored to-
gether with that of BLUE-1 K10 and BLUE-1. The iden-
tical STR profile and IGH chain gene rearrangement
patterns indicate that both cell lines indeed originate
from the same parent. Nevertheless, the differences ob-
served between BLUE-1, BLUE-1 K10 and BLUE-1R10
upon genomic interrogation using the OncoScan CNV
assay could suggest a divergent genomic evolution be-
tween BLUE-1 K10 and BLUE-1R10 cell lines in culture.
Since AHCY is a direct target of DZNep-mediated
EZH2 inhibition, we focused on validating the identified
AHCY gain in the resistant clone. Using the TaqMan
Copy Number Assay, which measures gene copy num-
bers by incorporating the TaqMan copy number assay
with the TaqMan copy number reference assay in a sin-
gle real-time PCR run, validation of AHCY amplification
was achieved on the DNA level. The progressive increase
in the AHCY copy number observed from BLUE-1R6
confirms that the gain in copy number is continual in
the DZNep-resistant clone. It is noteworthy that at the
point of DZNep withdrawal from the clone (from BLUE-
1R9 to BLUE-1R10), there was an almost two-fold in-
crease in the AHCY copy number. This copy number
gain doubled following continuous cultivation of the
clone in a DZNep-free medium (from BLUE-1R10 to
BLUE-1R11 and BLUE-1R12). This implies that the
AHCY copy number gain, once initiated, does not re-
quire DZNep pressure to persist. Although this copy
number event may reflect a sort of genomic compensa-
tion in the resistant clone due to prolonged AHCY in-
hibition, it is unlikely that this genomic aberration
Fig. 4 Translational validation of AHCY gain in the resistant clone, and metabolomics analysis. a IHC results from BLUE-1, BLUE-1 K12 and BLUE-
1R12 cell lines. Sections from FFPE cell line blocks were stained with anti-AHCY antibody. b Validation of AHCY overexpression at the protein level
using Western blot. Whole cell protein lysates from the cell lines were analyzed using Western blot. Histone 3 was used as a loading control for
the blot. The full-length blot is presented in Additional file 7: Fig. S6. FUSION-CAP Software was used for Western blot image analysis. c
Quantification of S-adenosyl methionine, adenine and adenosine in BLUE-1, BLUE-1 K12 and BLUE-1R12. Values are shown as mean plus SD from
six replicate measurements
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would decrease to baseline levels upon prolonged with-
drawal of DZNep pressure.
Moreover, the FISH data which revealed that the
AHCY amplification was more pronounced in BLUE-
1R12 in comparison to BLUE-1R10 further affirms the
persistence of AHCY copy number gain. The chromo-
some 20 polysomy observed in the cells of each cell line
may reflect the level of genomic instability usually occur-
ring in cancer cells [52, 53]. The overexpression of
AHCY on the transcriptional and protein level in the
DZNep-resistant clone is consistent with the knowledge
of drug resistance in cancer stemming from alterations
in the drug target, particularly, alterations involving
modified enzyme expression [46, 54]. Alterations in the
apoptotic machinery did not appear to be involved in
the resistance of the resistant clone to apoptosis based
on its RNA expression profile.
The results of our metabolomics studies which re-
vealed an analogous distribution for SAH, adenine and
adenosine in both BLUE-1 and BLUE-1 K12 signifies
that following long-term culture of BLUE-1, there is no
peculiar alteration of the balance exerted by these inter-
mediates within the cell. The increase in adenine and ad-
enosine levels of the resistant clone (BLUE-1R12) when
compared to BLUE-1 K12 is in line with the increased
expression of AHCY, which catalyzes the hydrolysis of
SAH to adenosine and L-homocysteine.
Previous works have linked copy number gains on
chromosome 20q with the pathogenesis of tumors such
as colon cancer [55], colorectal cancer [56], and cervical
cancer [57], with significant gains of the AHCY gene
among others. However, little is known about the role of
AHCY copy number gain in driving B-cell lymphomas.
For this reason, we analyzed the AHCY copy number of
12 primary lymphoma samples using the TaqMan CNV
assay. The absence of AHCY copy number gain in the
patient samples analyzed implies that it is unlikely that
AHCY copy number gains play a driving role in B-cell
lymphoma pathogenesis. In addition, the absence of
AHCY copy number alterations from in silico studies
signifies that alterations in AHCY are rare in primary B-
cell lymphoma however, in solid tumors, the frequency
of AHCY amplification can be as high as 20% [41, 42].
Conclusion
Acquired drug resistance poses a great challenge in can-
cer therapy. It is important to recognize mechanisms of
resistance for novel drugs about to enter clinical trials so
that one can monitor for early signs of development of
drug resistance. DZNep is a promising epigenetic drug
that is in the pre-clinical phase of clinical approval, but
has shown promising effects for selected cancer patients.
We show that copy number gain of AHCY is one pos-
sible mechanism of acquired resistance to DZNep-
mediated apoptosis and propose AHCY as a potential
biomarker to stratify patients during the use of DZNep.
Although AHCY alterations are rare in primary B-cell
lymphomas, it may still be important to screen for modi-
fications of this gene in patients prior to the initiation of
EZH2 based therapy with DZNep. These findings might
be valuable in predicting patients, who will benefit from
EZH2 inhibition using DZNep once it progresses into
clinical studies.
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